EP2464741A4 - Methods of detecting responses to therapies using perforin levels - Google Patents

Methods of detecting responses to therapies using perforin levels

Info

Publication number
EP2464741A4
EP2464741A4 EP10808602.6A EP10808602A EP2464741A4 EP 2464741 A4 EP2464741 A4 EP 2464741A4 EP 10808602 A EP10808602 A EP 10808602A EP 2464741 A4 EP2464741 A4 EP 2464741A4
Authority
EP
European Patent Office
Prior art keywords
therapies
methods
detecting responses
perforin levels
perforin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10808602.6A
Other languages
German (de)
French (fr)
Other versions
EP2464741A1 (en
Inventor
Ramesh C Nayak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2464741A1 publication Critical patent/EP2464741A1/en
Publication of EP2464741A4 publication Critical patent/EP2464741A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP10808602.6A 2009-08-10 2010-08-09 Methods of detecting responses to therapies using perforin levels Withdrawn EP2464741A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23260509P 2009-08-10 2009-08-10
PCT/US2010/044921 WO2011019670A1 (en) 2009-08-10 2010-08-09 Methods of detecting responses to therapies using perforin levels

Publications (2)

Publication Number Publication Date
EP2464741A1 EP2464741A1 (en) 2012-06-20
EP2464741A4 true EP2464741A4 (en) 2013-05-22

Family

ID=43586421

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10808602.6A Withdrawn EP2464741A4 (en) 2009-08-10 2010-08-09 Methods of detecting responses to therapies using perforin levels

Country Status (3)

Country Link
EP (1) EP2464741A4 (en)
CA (1) CA2770680A1 (en)
WO (1) WO2011019670A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106885902B (en) * 2017-03-03 2018-02-27 四川大学华西第二医院 It is gold-labeled kit of Testing index and its preparation method and application with NCAM 1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070048264A1 (en) * 2004-05-20 2007-03-01 Zymogenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511121B2 (en) * 2001-03-09 2009-03-31 Arnason Barry G W Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
JP2007526774A (en) * 2004-03-01 2007-09-20 ピーター・マッカラム・キャンサー・インスティテュート Recombinant perforin, its expression and its use
US8034613B2 (en) * 2005-06-01 2011-10-11 Wisconsin Alumni Research Foundation Multipotent lymphohematopoietic progenitor cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070048264A1 (en) * 2004-05-20 2007-03-01 Zymogenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AL-FALAHI, Y., ET AL: "Splenic natural killer cell activity in two models of experimental neurodegenerative diseases", J. CELL. MOL. MED., vol. 13, no. 8B, 29 December 2008 (2008-12-29), pages 2693 - 2703, XP002694229 *
GORDANA RUBESA ET AL: "Increased perforin expression in multiple sclerosis patients during exacerbation of disease in peripheral blood lymphocytes", JOURNAL OF NEUROIMMUNOLOGY, vol. 74, no. 1-2, 1 April 1997 (1997-04-01), pages 198 - 204, XP055057332, ISSN: 0165-5728, DOI: 10.1016/S0165-5728(96)00236-6 *
NAYAK, R.C. AND JACOLIK, R.F.: "CD16+/Perforin+ Lymphocytes (NK Cells) Regulate Autoimmunity in Multiple Sclerosis by Cytolysis of Antigen Laden Cells in thePeripheral Blood", 20 April 2012 (2012-04-20), XP002694230, Retrieved from the Internet <URL:http://www.msdx.co/assets/docs/2012%20NK%20Conference%20-%20NK%20Cells%20and%20MS.pdf> [retrieved on 20130318] *
RATTS R B ET AL: "CD28<->CD57<+> T cells predominate in CD8 responses to glatiramer acetate", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 178, no. 1-2, 1 September 2006 (2006-09-01), pages 117 - 129, XP027901498, ISSN: 0165-5728 *
See also references of WO2011019670A1 *

Also Published As

Publication number Publication date
WO2011019670A1 (en) 2011-02-17
CA2770680A1 (en) 2011-02-17
EP2464741A1 (en) 2012-06-20

Similar Documents

Publication Publication Date Title
HK1246328A1 (en) Methods of purifying polypepides
EP2539019A4 (en) Concurrent stimulation effect detection
EP2675361A4 (en) Photoacoustic probe
ZA201101641B (en) Use of mtor inhibitors to enhance t cell immune responses
IL228066A0 (en) Methods of detecting aneuploidy in human embryos
EP2596117A4 (en) Methods of detecting kidney-associated diseases or conditions
SG11201401212TA (en) Probe unit
EP2561795A4 (en) Probe
EP2798633A4 (en) Acoustic signal modification
EP2756118A4 (en) Methods of detecting sepsis
EP2653103A4 (en) Percussion structure of lancing device
EP2596349A4 (en) Methods of detecting cardiovascular diseases or conditions
GB201005624D0 (en) Probe
EP2588428A4 (en) Methods of kinome analysis
EP2633796A4 (en) Probe
EP2598875A4 (en) Biomechanical-based methods of diagnosing scoliosis
GB201119005D0 (en) Ultrasound probe
GB201012078D0 (en) Concentration measurement using luminescene
TWM388611U (en) Improved structure of light-emitting device
GB201004710D0 (en) Detection of mycobacteria
GB201002261D0 (en) Detection of signals
SI2362711T1 (en) Failure detection of LEDs
EP2464741A4 (en) Methods of detecting responses to therapies using perforin levels
EP2742870A4 (en) Ultrasound probe
EP2653090A4 (en) Probe

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20130328BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20130419

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20130412BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131119